This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Johns Hopkins Antibiotic Resistance Center | |
|---|---|
| Name | Johns Hopkins Antibiotic Resistance Center |
| Established | 2017 |
| Type | Research center |
| Location | Baltimore, Maryland, United States |
| Director | Ramanan Laxminarayan |
| Parent | Johns Hopkins Bloomberg School of Public Health |
Johns Hopkins Antibiotic Resistance Center is a research and policy center focused on antimicrobial resistance and infectious disease control. It combines laboratory research, epidemiology, data science, and policy analysis to address bacterial resistance, antibiotic stewardship, and global health threats. The center collaborates with academic institutions, public health agencies, and international organizations to translate evidence into interventions and guidance.
The center was launched from initiatives at the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins University building on prior work by scholars associated with the Center for Disease Dynamics, Economics & Policy and networks such as the Global Antibiotic Resistance Partnership and the WHO initiatives on antimicrobial resistance. Early collaborators included investigators from the National Institutes of Health, the Centers for Disease Control and Prevention, and the London School of Hygiene & Tropical Medicine. Its formation followed global momentum after landmark reports from the Review on Antimicrobial Resistance chaired by Jim O'Neill and high-level policy actions by the G20 and the United Nations General Assembly on antimicrobial resistance. Founding activities connected with surveillance platforms used in projects funded by the Bill & Melinda Gates Foundation and partnerships with the Wellcome Trust.
The center's stated mission aligns with strategic priorities outlined by the World Health Organization's Global Action Plan, aiming to reduce antimicrobial resistance burden in clinical care and public health. Goals emphasize integrating clinical microbiology expertise from institutions such as the Mayo Clinic and Massachusetts General Hospital with policy translation similar to work by the Brookings Institution and RAND Corporation. The center seeks to inform regulators like the Food and Drug Administration and ministries of health through evidence-generation akin to analyses published by the European Centre for Disease Prevention and Control.
Research programs span basic science, translational studies, and health systems research. Microbial genomics efforts collaborate with sequencing centers such as the Broad Institute and the Wellcome Sanger Institute to study resistance mechanisms in pathogens like Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Clinical trials and stewardship interventions have been designed with partners including Johns Hopkins Hospital and University College London Hospitals NHS Foundation Trust. Modeling and economic evaluations draw on methods from the Imperial College London and the University of Oxford research groups that contributed to pandemic modeling. Laboratory collaborations include work with the Howard Hughes Medical Institute and the Cold Spring Harbor Laboratory on novel antimicrobial discovery and resistance evolution.
Surveillance activities aggregate antibiotic usage and resistance data, interoperating with platforms from the European Antimicrobial Resistance Surveillance Network and the Global Antimicrobial Resistance Surveillance System. The center has developed databases and dashboards in partnership with data science teams at the Johns Hopkins Coronavirus Resource Center and analytics groups similar to those at the Institute for Health Metrics and Evaluation. International surveillance partnerships include collaborations with the African CDC, the Pan American Health Organization, and national public health institutes such as the Public Health England and the National Institute for Communicable Diseases (South Africa). Data-sharing agreements mirror frameworks used by the Global Health Security Agenda.
Training programs target clinicians, microbiologists, and public health professionals, offering curricula influenced by continuing education models at Harvard Medical School and Yale School of Medicine. The center sponsors fellowships and workshops in antibiotic stewardship with partners like the Society for Healthcare Epidemiology of America, the Infectious Diseases Society of America, and the American Society for Microbiology. Global training initiatives coordinate with academic programs at the University of Cape Town, the All India Institute of Medical Sciences, and the Universidad Peruana Cayetano Heredia to build capacity in low- and middle-income settings.
Policy engagement includes producing evidence briefs and technical guidance for multilateral bodies such as the United Nations, the G7, and the World Bank. Advocacy and stakeholder engagement mimic strategies used by the Global Fund and UNAIDS to mobilize financing and political will. The center convenes consortia involving pharmaceutical firms like Pfizer and GlaxoSmithKline, diagnostics companies, and nonprofit actors including PATH and Médecins Sans Frontières to align research priorities and stewardship initiatives.
Funding sources include grants and contracts from foundations such as the Bill & Melinda Gates Foundation and the Wellcome Trust, government research agencies including the National Institutes of Health and the European Commission, and philanthropic and philanthropic-industry partnerships modeled after arrangements by the Chan Zuckerberg Initiative. Organizationally, the center is embedded within the Johns Hopkins Bloomberg School of Public Health and works across departmental hubs including the Department of Epidemiology, the Department of Molecular Microbiology and Immunology, and the Center for Health Security. Governance involves advisory boards with members drawn from academia, clinical practice, and international health agencies including former leaders from the CDC Foundation and the World Health Organization.